Theratechnologies Inc. (THTX)
USD 2.57
(32.47%)
USD 2.57
(32.47%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -23.95 Million USD | 49.28% |
| 2022 | -47.23 Million USD | -48.9% |
| 2021 | -31.72 Million USD | -39.96% |
| 2020 | -22.66 Million USD | -81.39% |
| 2019 | -12.49 Million USD | -176.21% |
| 2018 | -4.52 Million USD | 68.37% |
| 2017 | -14.3 Million USD | -4784.42% |
| 2016 | 305.29 Thousand USD | -74.1% |
| 2015 | 1.17 Million USD | 112.76% |
| 2014 | -9.23 Million USD | -141.28% |
| 2013 | -3.82 Million USD | 72.72% |
| 2012 | -14.03 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 987 Thousand USD | 122.25% |
| 2024 Q1 | -4.43 Million USD | -61.04% |
| 2024 Q3 | 3.09 Million USD | 213.17% |
| 2023 Q1 | -10.44 Million USD | -31.71% |
| 2023 Q4 | -2.75 Million USD | -269.3% |
| 2023 Q2 | -10.01 Million USD | 4.12% |
| 2023 FY | -23.95 Million USD | 49.28% |
| 2023 Q3 | -746 Thousand USD | 92.55% |
| 2022 Q4 | -7.92 Million USD | -5.03% |
| 2022 Q2 | -22.72 Million USD | -151.63% |
| 2022 FY | -47.23 Million USD | -48.9% |
| 2022 Q1 | -9.03 Million USD | 8.78% |
| 2022 Q3 | -7.54 Million USD | 66.78% |
| 2021 Q1 | -5.92 Million USD | -6.72% |
| 2021 Q3 | -9.51 Million USD | -48.78% |
| 2021 FY | -31.72 Million USD | -39.96% |
| 2021 Q2 | -6.39 Million USD | -7.94% |
| 2021 Q4 | -9.9 Million USD | -4.11% |
| 2020 Q3 | -6.76 Million USD | -16.57% |
| 2020 FY | -22.66 Million USD | -81.39% |
| 2020 Q1 | -4.54 Million USD | 29.6% |
| 2020 Q2 | -5.8 Million USD | -27.77% |
| 2020 Q4 | -5.54 Million USD | 18.01% |
| 2019 Q2 | -3.17 Million USD | -158.47% |
| 2019 Q4 | -6.45 Million USD | -293.84% |
| 2019 FY | -12.49 Million USD | -176.21% |
| 2019 Q1 | -1.22 Million USD | -24.92% |
| 2019 Q3 | -1.63 Million USD | 48.36% |
| 2018 Q3 | 282 Thousand USD | 114.75% |
| 2018 Q2 | -1.91 Million USD | 8.39% |
| 2018 Q1 | -2.08 Million USD | 36.14% |
| 2018 FY | -4.52 Million USD | 68.37% |
| 2018 Q4 | -983 Thousand USD | -448.58% |
| 2017 Q4 | -3.26 Million USD | -41.59% |
| 2017 Q2 | -6.74 Million USD | -299.31% |
| 2017 Q1 | -1.68 Million USD | -1460.68% |
| 2017 FY | -14.3 Million USD | -4784.42% |
| 2017 Q3 | -2.3 Million USD | 65.78% |
| 2016 Q3 | 678.34 Thousand USD | 278.39% |
| 2016 Q2 | -380.26 Thousand USD | -236.32% |
| 2016 Q4 | 124.11 Thousand USD | -81.7% |
| 2016 Q1 | -113.06 Thousand USD | -131.67% |
| 2016 FY | 305.29 Thousand USD | -74.1% |
| 2015 FY | 1.17 Million USD | 112.76% |
| 2015 Q4 | 357.06 Thousand USD | -59.9% |
| 2015 Q1 | -730.47 Thousand USD | 76.97% |
| 2015 Q3 | 890.35 Thousand USD | 35.27% |
| 2015 Q2 | 658.19 Thousand USD | 190.11% |
| 2014 Q1 | -3.18 Million USD | -29.99% |
| 2014 Q2 | 928.04 Thousand USD | 129.1% |
| 2014 Q3 | -4.04 Million USD | -536.1% |
| 2014 Q4 | -3.17 Million USD | 21.61% |
| 2014 FY | -9.23 Million USD | -141.28% |
| 2013 Q3 | -1.83 Million USD | -37.28% |
| 2013 Q2 | -1.33 Million USD | -173.54% |
| 2013 FY | -3.82 Million USD | 72.72% |
| 2013 Q1 | 1.81 Million USD | 141.58% |
| 2013 Q4 | -2.45 Million USD | -33.73% |
| 2012 Q1 | -7.52 Million USD | -862.24% |
| 2012 Q4 | -4.36 Million USD | -521.71% |
| 2012 Q2 | -1.37 Million USD | 81.73% |
| 2012 Q3 | -702.88 Thousand USD | 48.88% |
| 2012 FY | -14.03 Million USD | 0.0% |
| 2011 Q2 | -6.08 Million USD | -0.27% |
| 2011 Q4 | -782.28 Thousand USD | 81.64% |
| 2011 Q1 | -6.06 Million USD | -129.7% |
| 2011 Q3 | -4.25 Million USD | 29.96% |
| 2010 Q3 | -3.16 Million USD | 29.99% |
| 2010 Q2 | -4.52 Million USD | -12.07% |
| 2010 Q1 | -4.03 Million USD | 15.55% |
| 2010 Q4 | 20.42 Million USD | 745.07% |
| 2009 Q3 | 5.31 Million USD | 206.27% |
| 2009 Q1 | -8.47 Million USD | -7.63% |
| 2009 Q2 | -5 Million USD | 40.93% |
| 2009 Q4 | -4.77 Million USD | -189.85% |
| 2008 Q3 | -10.56 Million USD | 7.73% |
| 2008 Q1 | -11.08 Million USD | 5.39% |
| 2008 Q2 | -11.44 Million USD | -3.27% |
| 2008 Q4 | -7.87 Million USD | 25.49% |
| 2007 Q2 | -7.56 Million USD | 6.21% |
| 2007 Q3 | -9.25 Million USD | -22.43% |
| 2007 Q1 | -8.06 Million USD | -45.56% |
| 2007 Q4 | -11.71 Million USD | -26.52% |
| 2006 Q3 | -6.55 Million USD | -16.1% |
| 2006 Q1 | -4.78 Million USD | 3.53% |
| 2006 Q2 | -5.65 Million USD | -18.03% |
| 2006 Q4 | -5.54 Million USD | 15.54% |
| 2005 Q1 | 7.51 Million USD | 174.27% |
| 2005 Q3 | -4.39 Million USD | 56.75% |
| 2005 Q4 | -4.96 Million USD | -12.96% |
| 2005 Q2 | -10.15 Million USD | -235.17% |
| 2004 Q3 | -3.16 Million USD | 27.12% |
| 2004 Q1 | -1.41 Million USD | 87.85% |
| 2004 Q2 | -4.33 Million USD | -207.39% |
| 2004 Q4 | -10.11 Million USD | -220.02% |
| 2003 Q3 | -4.75 Million USD | 11.68% |
| 2003 Q4 | -11.61 Million USD | -144.31% |
| 2003 Q2 | -5.38 Million USD | -38.89% |
| 2003 Q1 | -3.87 Million USD | 22.04% |
| 2002 Q4 | -4.97 Million USD | -60.3% |
| 2002 Q1 | -1.01 Million USD | 72.78% |
| 2002 Q2 | -42.53 Thousand USD | 95.82% |
| 2002 Q3 | -3.1 Million USD | -7190.91% |
| 2001 Q1 | -1.53 Million USD | -154.72% |
| 2001 Q4 | -3.73 Million USD | -118.32% |
| 2001 Q3 | 20.41 Million USD | 1008.16% |
| 2001 Q2 | 1.84 Million USD | 219.98% |
| 2000 Q1 | -1.03 Million USD | -4.87% |
| 2000 Q2 | -1.46 Million USD | -42.04% |
| 2000 Q3 | 3.49 Million USD | 338.1% |
| 2000 Q4 | 2.8 Million USD | -19.74% |
| 1999 Q4 | -985.74 Thousand USD | -22.77% |
| 1999 Q3 | -802.91 Thousand USD | 1.34% |
| 1999 Q1 | -729.2 Thousand USD | -0.44% |
| 1999 Q2 | -813.84 Thousand USD | -11.61% |
| 1998 Q3 | -885.85 Thousand USD | 7.83% |
| 1998 Q4 | -726.03 Thousand USD | 18.04% |
| 1998 Q1 | -983.69 Thousand USD | -28.44% |
| 1998 Q2 | -961.14 Thousand USD | 2.29% |
| 1997 Q1 | -1.02 Million USD | 0.0% |
| 1997 Q4 | -765.88 Thousand USD | 24.01% |
| 1997 Q2 | -1.3 Million USD | -27.68% |
| 1997 Q3 | -1 Million USD | 22.83% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 149.75% |
| Embecta Corp. | 70.4 Million USD | 134.03% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 227.573% |
| Dynavax Technologies Corporation | -6.38 Million USD | -274.973% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 88.551% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 157.102% |
| PainReform Ltd. | -9.34 Million USD | -156.389% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -204.409% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -431.664% |
| SCYNEXIS, Inc. | 67.04 Million USD | 135.735% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -673.173% |
| Cosmos Health Inc. | -18.54 Million USD | -29.199% |
| Journey Medical Corporation | -3.85 Million USD | -521.775% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -431.664% |
| Safety Shot Inc | -15.08 Million USD | -58.834% |
| Alpha Teknova, Inc. | -36.78 Million USD | 34.864% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 82.848% |
| Bright Green Corporation | -13.12 Million USD | -82.493% |
| Procaps Group, S.A. | 42.54 Million USD | 156.316% |
| Harrow Health, Inc. | -24.41 Million USD | 1.86% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -395.491% |
| Biofrontera Inc. | -20.13 Million USD | -19.006% |
| DURECT Corporation | -27.62 Million USD | 13.275% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1920.441% |
| Cronos Group Inc. | -73.96 Million USD | 67.609% |
| OptiNose, Inc. | -35.48 Million USD | 32.483% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 97.61% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 43.229% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 200.171% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 584.469% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 15259.492% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -281.522% |
| Radius Health, Inc. | -25.79 Million USD | 7.111% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -288.719% |
| ProPhase Labs, Inc. | -16.78 Million USD | -42.754% |
| Phibro Animal Health Corporation | 2.41 Million USD | 1091.598% |
| Procaps Group S.A. | 42.54 Million USD | 156.316% |
| Alvotech | -551.73 Million USD | 95.658% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -133.09% |
| Viatris Inc. | 54.7 Million USD | 143.797% |
| Rockwell Medical, Inc. | -8.43 Million USD | -183.884% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -51.206% |
| SIGA Technologies, Inc. | 68.06 Million USD | 135.195% |
| Tilray Brands, Inc. | -244.98 Million USD | 90.221% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 299.426% |
| Shineco, Inc. | -22.44 Million USD | -6.717% |
| PetIQ, Inc. | 2.13 Million USD | 1224.214% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -456.902% |
| Incannex Healthcare Limited | -18.45 Million USD | -29.785% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 109.594% |
| Alimera Sciences, Inc. | -20.13 Million USD | -19.0% |
| Silver Spike Investment Corp. | 7.34 Million USD | 426.385% |
| Assertio Holdings, Inc. | -331.94 Million USD | 92.783% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -263.386% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -193.476% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -33.845% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -19.443% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 85.053% |
| Hempacco Co., Inc. | -13.12 Million USD | -82.514% |
| Talphera, Inc. | -18.39 Million USD | -30.222% |
| Alvotech | -551.73 Million USD | 95.658% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 167.216% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 107.334% |
| Currenc Group, Inc. | -15.3 Million USD | -56.515% |
| Kamada Ltd. | 8.28 Million USD | 389.196% |
| Indivior PLC | 2 Million USD | 1297.85% |
| Evoke Pharma, Inc. | -7.79 Million USD | -207.445% |
| Flora Growth Corp. | -57.03 Million USD | 57.997% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -19.443% |
| Evolus, Inc. | -61.68 Million USD | 61.162% |
| HUTCHMED (China) Limited | 100.78 Million USD | 123.772% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 117.418% |
| Akanda Corp. | -32.27 Million USD | 25.772% |